ChemoCentryx (CCXI) Tops Q3 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to ChemoCentryx (CCXI) Tops Q3 EPS by 13c

ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights

November 9, 2021 4:05 PM EST

-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October --

-- TAVNEOS now launched in the U.S. --

-- TAVNEOS approved also in Japan; European CHMP opinion expected this month --

-- Pipeline advances: Company intends to meet with FDA on path for TAVNEOS in C3 Glomerulopathy (C3G) and Hidradenitis Suppurativa (HS); plans to initiate clinical development of TAVNEOS in Lupus Nephritis (LN) in 2022 --

-- Clinical development underway of next... More